Surrozen Logo FINAL Large-1.png
Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis
03 avr. 2024 08h40 HE | Surrozen, Inc.
Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis
Surrozen Logo FINAL Large-1.png
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
01 avr. 2024 08h30 HE | Surrozen, Inc.
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
Surrozen Logo FINAL Large-1.png
Surrozen Provides Corporate Update on Clinical Programs
18 janv. 2024 08h30 HE | Surrozen, Inc.
Announces strategic prioritization of clinical programs to focus on development of SZN-043 for Alcohol-Associated Hepatitis SZN-043- Completed enrollment for the Phase 1a clinical trial in chronic...
Surrozen Logo FINAL Large-1.png
Surrozen Provides Third Quarter 2023 Financial Results
08 nov. 2023 16h05 HE | Surrozen, Inc.
Expect to announce data from SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers in Q1 2024 Expect to announce data from SZN-1326 Phase 1a clinical...